On January 17, 2013, the first subject completed in-person screening for our new Israeli study of MDMA-assisted psychotherapy for PTSD, led by Principal Investigator Moshe Kotler, M.D., and monitored by Clinical Research Associate Mimi Peleg. This study has the approval of the Israeli Ministry of Health, the Ethics Committee at Beer Yaakov Mental Health Center, and the Israeli Anti-Drug Authority. The protocol has also been approved by the U.S. Food and Drug Administration, which reviews all of the data from our Phase 2 drug development program. The Israeli Defense Forces will refer soldiers with war-related PTSD to facilitate recruitment for the study.